Shares of India’s largest pharmaceutical company, which surged to its seven-year high earlier on Wednesday, advanced 1.45% to close at ₹1,051.60. It touched a high of ₹1,070.95 before giving up some of its gains. Analysts have a median target price of ₹1,135.28 per share. That translates roughly into gains of 8.3% from the current market price.
Can Moneyview IPO deliver long-term growth for high-risk investors?
Moneyview, a digital lending platform, is planning a ₹750 crore IPO to fund loan growth. The company’s registered users increased significantly, but asset quality has